Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 17;21(18):6827.
doi: 10.3390/ijms21186827.

Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application

Affiliations
Review

Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application

Melinda Szilágyi et al. Int J Mol Sci. .

Abstract

Liquid biopsy recently became a very promising diagnostic method that has several advantages over conventional invasive methods. Liquid biopsy may serve as a source of several important biomarkers including cell-free nucleic acids (cf-NAs). Cf-DNA is widely used in prenatal testing in order to characterize fetal genetic disorders. Analysis of cf-DNA may provide information about the mutation profile of tumor cells, while cell-free non-coding RNAs are promising biomarker candidates in the diagnosis and prognosis of cancer. Many of these markers have the potential to help clinicians in therapy selection and in the follow-up of patients. Thus, cf-NA-based diagnostics represent a new path in personalized medicine. Although several reviews are available in the field, most of them focus on a limited number of cf-NA types. In this review, we give an overview about all known cf-NAs including cf-DNA, cf-mtDNA and cell-free non-coding RNA (miRNA, lncRNA, circRNA, piRNA, YRNA, and vtRNA) by discussing their biogenesis, biological function and potential as biomarker candidates in liquid biopsy. We also outline possible future directions in the field.

Keywords: biological fluids; cell-free nucleic acids; circRNA; exosomes; liquid biopsy; lncRNA; miRNA; mtDNA; nDNA.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

Figures

Figure 1
Figure 1
Utilization of cell-free Nucleic Acids in cancer diagnostics and treatment.
Figure 2
Figure 2
Cell-free RNA molecules in serum/plasma with their biological function.

References

    1. Heitzer E., Haque I.S., Roberts C.E.S., Speicher M.R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 2018;20:71–88. doi: 10.1038/s41576-018-0071-5. - DOI - PubMed
    1. Bayraktar R., Van Roosbroeck K., Calin G.A. Cell-to-cell communication: MicroRNAs as hormones. Mol. Oncol. 2017;11:1673–1686. doi: 10.1002/1878-0261.12144. - DOI - PMC - PubMed
    1. Alimirzaie S., Bagherzadeh M., Akbari M.R. Liquid biopsy in breast cancer: A comprehensive review. Clin. Genet. 2019;95:643–660. doi: 10.1111/cge.13514. - DOI - PubMed
    1. Jahr S., Hentze H., Englisch S., Hardt D., O Fackelmayer F., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665. - PubMed
    1. Pös O., Bíró O., Szemes T., Nagy B. Circulating cell-free nucleic acids: Characteristics and applications. Eur. J. Hum. Genet. 2018;26:937–945. doi: 10.1038/s41431-018-0132-4. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources